ea0099p521 | Pituitary and Neuroendocrinology | ECE2024
Castinetti Frederic
, Geer Eliza
, Biller Beverly
, Feelders Richard
, Fleseriu Maria
, Pivonello Rosario
, Reincke Martin
, Tabarin Antoine
, Le Mouhaer Jeannie
, Stermenska Julia
, Maldonado Mario
, Bancos Irina
Introduction: Potent 11β-hydroxylase inhibitor osilodrostat provides cortisol level control in patients with Cushings syndrome (CS), as demonstrated by the LINC clinical development programme in Cushings disease (CD) patients.1 We report data from year 1 of the prospective observational LINC6 study (NCT05382156), evaluating long-term safety and efficacy of osilodrostat in CS patients during 3 years of routine clinical practice.<p class="abstext"...